These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 82772)

  • 21. Fatal deterioration of Wilson's disease after institution of oral zinc therapy.
    Lang CJ; Rabas-Kolominsky P; Engelhardt A; Kobras G; Konig HJ
    Arch Neurol; 1993 Oct; 50(10):1007-8. PubMed ID: 8280286
    [No Abstract]   [Full Text] [Related]  

  • 22. [Effectiveness of zinc sulfate in the treatment of Wilson's disease].
    Jonderko G; Pluta H; Wieczorek U
    Pol Tyg Lek; 1988 Apr; 43(14):459-60. PubMed ID: 3412983
    [No Abstract]   [Full Text] [Related]  

  • 23. Wilson's disease in south India and experience with zinc therapy.
    Murthy BS; Murthy JM; Krishnaveni A; Reddy MV; Das SM
    J Assoc Physicians India; 1988 Jul; 36(7):417-9. PubMed ID: 3204085
    [No Abstract]   [Full Text] [Related]  

  • 24. [Control of the therapeutic prevention of copper uptake in the liver in Wilson's disease following oral administration of 64Cu].
    Günther K; Siegemund R; Lössner J; Kühn HJ
    Radiobiol Radiother (Berl); 1988; 29(2):226-9. PubMed ID: 3399664
    [No Abstract]   [Full Text] [Related]  

  • 25. Treatment of Wilson's disease.
    Brewer GJ; Yuzbasiyan-Gurkan V; Young AB
    Semin Neurol; 1987 Jun; 7(2):209-20. PubMed ID: 3332455
    [No Abstract]   [Full Text] [Related]  

  • 26. Interactions of zinc and molybdenum with copper in therapy of Wilson's disease.
    Brewer GJ
    Nutrition; 1995; 11(1 Suppl):114-6. PubMed ID: 7749256
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of Wilson's disease with zinc: XI. Interaction with other anticopper agents.
    Brewer GJ; Yuzbasiyan-Gurkan V; Johnson V; Dick RD; Wang Y
    J Am Coll Nutr; 1993 Feb; 12(1):26-30. PubMed ID: 8440814
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Zinc treatment prevents lipid peroxidation and increases glutathione availability in Wilson's disease.
    Farinati F; Cardin R; D'inca R; Naccarato R; Sturniolo GC
    J Lab Clin Med; 2003 Jun; 141(6):372-7. PubMed ID: 12819634
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Zinc therapy increases duodenal concentrations of metallothionein and iron in Wilson's disease patients.
    Sturniolo GC; Mestriner C; Irato P; Albergoni V; Longo G; D'Incà R
    Am J Gastroenterol; 1999 Feb; 94(2):334-8. PubMed ID: 10022625
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The treatment of sickle cell anemia and Wilson's disease with zinc.
    Brewer GJ; Hill GM
    Prog Clin Biol Res; 1983; 127():97-113. PubMed ID: 6889406
    [No Abstract]   [Full Text] [Related]  

  • 31. [The role of zinc in the initial treatment of Wilson's disease in children].
    Cacić M; Percl M; Jadresin O; Kolacek S
    Lijec Vjesn; 2000 Mar; 122(3-4):77-81. PubMed ID: 10932534
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Effect of oral ZnSO4 on urine copper and blood trace elements in 60 patients with Wilson's disease].
    Yang RM
    Zhonghua Yi Xue Za Zhi; 1986 Apr; 66(4):211-3, 254. PubMed ID: 3094875
    [No Abstract]   [Full Text] [Related]  

  • 33. Use of whole-body counter to study body retention of radiocopper in Wilson's disease.
    Hamamoto K; Tauxe WN; Novak LP; Goldstein NP
    J Lab Clin Med; 1968 Nov; 72(5):754-9. PubMed ID: 5697385
    [No Abstract]   [Full Text] [Related]  

  • 34. Using zinc to remove copper from pediatric patients with Wilson's disease.
    Klevay LM
    J Lab Clin Med; 2001 Sep; 138(3):214. PubMed ID: 11548740
    [No Abstract]   [Full Text] [Related]  

  • 35. Zinc therapy in Wilson's disease: observations in five patients.
    Rossaro L; Sturniolo GC; Giacon G; Montino MC; Lecis PE; Schade RR; Corazza GR; Trevisan C; Naccarato R
    Am J Gastroenterol; 1990 Jun; 85(6):665-8. PubMed ID: 2353684
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of Wilson's disease with zinc: X. Intestinal metallothionein induction.
    Yuzbasiyan-Gurkan V; Grider A; Nostrant T; Cousins RJ; Brewer GJ
    J Lab Clin Med; 1992 Sep; 120(3):380-6. PubMed ID: 1517684
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Treatment of Wilson's disease with Zincteral].
    Kuczyńska-Zardzewiały A; Rodo M; Członkowska A
    Neurol Neurochir Pol; 1988; 22(3):211-5. PubMed ID: 3221958
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Wilson's disease.
    Walshe JM
    Biochem J; 1969 Feb; 111(3):8P-9P. PubMed ID: 5767059
    [No Abstract]   [Full Text] [Related]  

  • 39. Regression of Kayser-Fleischer rings during oral zinc therapy: correlation with systemic manifestations of Wilson's disease.
    Esmaeli B; Burnstine MA; Martonyi CL; Sugar A; Johnson V; Brewer GJ
    Cornea; 1996 Nov; 15(6):582-8. PubMed ID: 8899270
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The physiology of copper in man and its relation to Wilson's disease.
    Walshe JM
    Brain; 1967 Mar; 90(1):149-76. PubMed ID: 5336999
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.